CSIMarket Company Name, Ticker, Competitors, else..
 
Prokidney Corp   (NASDAQ: PROK)
 
Price: $1.8150 $0.02 0.833%
Day's High: $1.8450000286102295 Week Perf: -8.79 %
Day's Low: $ 1.79 30 Day Perf: 29.18 %
Volume (M): 649,470 52 Wk High: $ 3.48
Volume (M$): $ 0 52 Wk Avg: $2.11
Open: $1.80 52 Wk Low: $1.30



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) -
 Employees 231
 Revenues (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) -166
 Cash Flow (TTM) (Millions $) 17
 Capital Exp. (TTM) (Millions $) 19

Business Description


Prokidney Corp is a medical company that specializes in the development and manufacturing of innovative products for kidney care and treatment. They cater to patients with kidney diseases and disorders, providing them with advanced solutions to improve their quality of life. Prokidney Corp is known for its cutting-edge technology and research in the field of nephrology, constantly striving to find new and effective treatments for kidney-related ailments. They work closely with healthcare professionals to ensure the best outcomes for their patients, and their products are widely used in hospitals and healthcare facilities worldwide.


   Company Address: 2000 Frontis Plaza Blvd. Winston-Salem 27103 NC
   Company Phone Number: 999-7019   Stock Exchange / Ticker: NASDAQ PROK


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMGN   -13.21%    
BCRX   -18.07%    
BEAM   -17.43%    
EXEL   -4.59%    
GILD   -3.88%    
RGNX   -3.47%    
• View Complete Report
   



Clinical Study

ProKidneys Rilparencel Phase 2 Triumph Navigating CKD Treatment Landscape Amid Revenue Stagnation and Competitive ...

Published Thu, Nov 6 2025 8:06 PM UTC

The landscape of chronic kidney disease (CKD) therapeutics is rapidly evolving, with emerging cell therapies offering new hope for patients suffering from advanced stages of the disease. At the forefront of this innovation is ProKidney Corp. (Nasdaq: PROK), a late clinical-stage cell therapy company dedicated to addressing the dire unmet needs of CKD patients, particularly t...
Management Announcement

ProKidney Corp Raises $140 Million in Public and Direct Offering, Fueling Breakthroughs in Chronic Kidney Disease Therapeutics

Published Mon, Jun 17 2024 11:00 AM UTC

ProKidney Corp Announces Successful Closing of $140 Million Public Offering and Registered Direct Offering
ProKidney Corp, a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease, has recently completed a significant financial milestone. The company has successfully closed a public offering and concurrent registered direct offering,...
Shares

ProKidney Corp. Raises $125 Million in Public Offering to Combat Chronic Kidney Disease

Published Mon, Jun 10 2024 8:15 PM UTC

ProKidney Corp. Announces $125 Million Public Offering to Advance Treatment for Chronic Kidney Disease
ProKidney Corp., a leading cellular therapeutics company specializing in chronic kidney disease, has just announced a significant financial move to further advance its groundbreaking treatments. The company, listed on Nasdaq under the ticker symbol PROK, has kicked off ...
Clinical Study

ProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational Updates

Published Mon, Jun 10 2024 10:30 AM UTC

Renal Autologous Cell Therapy Shows Promise: Interim Results from ProKidney s REGEN-007 Phase 2 Trial Authors: Author Names, CSIMarket.com In a recent announcement, ProKidney Corp. (Nasdaq: PROK), a prominent late clinical-stage cellular therapeutics company specializing in chronic kidney disease (CKD), has reported encouraging interim results from its Phase 2 REGEN-007 tr...
Clinical Study

ProKidney Corp. Ushers in a Promising Era for CKD Treatment with Strong First Quarter Results

Published Fri, May 10 2024 11:01 AM UTC

ProKidney Corp. Reports Positive Business Updates and First Quarter Financial ResultsProKidney Corp., a renowned late-stage cellular therapeutics company specializing in chronic kidney disease (CKD), has recently released its business updates and financial results for the first quarter ending March 31, 2024. The positive outcomes highlight the company s progress in its missi...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 7.99
Working Capital Ratio 8.36
Leverage Ratio (MRQ) -
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.39 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash -
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 3,541
Net Income per Employee (TTM) -717,541
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0

Profitability Ratios Current
Gross Margin (MRQ) 0 %
Operating Margin (MRQ) -32248.67 %
Net Margin (MRQ) -30957.33 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Prokidney's Segments
Reportable Segment    250.67 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.